{
  "docId": "019de074-ad31-7288-aa0c-b4a964d6a9af",
  "docSlug": "31aafddb38d645745d1c40d83b8ae135",
  "documentTitle": "ATAI | Investor Presentation Deck | 30 slides",
  "authorId": "atai",
  "authorName": "atai",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 30,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "Includes a summary table on the left and a line chart showing clinical trial results on the right.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ad31-7288-aa0c-b4a964d6a9af/25",
  "deckHref": "/decks/019de074-ad31-7288-aa0c-b4a964d6a9af",
  "deckJsonHref": "/decks/019de074-ad31-7288-aa0c-b4a964d6a9af.json",
  "deckAnchorHref": "/decks/019de074-ad31-7288-aa0c-b4a964d6a9af#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.55,
        "x": 0.38,
        "y": 0.8
      },
      "kind": "callout",
      "text": "Atai is currently conducting a PH1 study for VLS-01 with an oral transmucosal film (OTF) formulation, which may simplify in-clinic administration relative to IV",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c8a0c9d-f30f-4cc5-bef7-6a628d0a36ba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.55,
        "x": 0.38,
        "y": 0.25
      },
      "kind": "chart",
      "text": "MADRS Score over time for Ayahuasca vs Placebo",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5af7a093-a7dd-489c-88bd-bd92445cc030",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.55,
        "x": 0.38,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "Note: MADRS = Montgomery-Asberg Depression Rate Scale, DMT = Dimethyltryptamine. 1. Unless otherwise indicated herein... 2. Palhano-Fontes et al... 3. Covering (i) DMT compositions...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "20812d60-1f4e-4706-a48a-97fa04412662",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.3,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "table",
      "text": "Ownership: 100%, Product: DMT oral film, Pharmacology: 5-HT2A-R agonist, Features: Rapid onset/short duration, Indications: TRD/Eating Disorders, Status: Phase 1, IP: Issued/pending patents, Highlight: Improved duration/tolerability",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f977a5f-b56d-41e2-b2fb-5e5a0d222e2d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.55,
        "x": 0.38,
        "y": 0.08
      },
      "kind": "title",
      "text": "VLS-01 may increase patient accessibility by reducing patient and clinic time commitment",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "52725088-791a-4e7e-be50-574acf8caaba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "SUMMARY: VLS-01",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "69423461-ed8f-4b2d-a4ae-723204610d89",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "fe88a54d-6bc4-4aae-bf43-185dd9a25520",
      "evidence": "The slide features a table comparing the characteristics of VLS-01 with other treatments.",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 30,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "8a640552-7d64-4f46-af4c-8041a39da251",
      "evidence": "The deck presents a clear and compelling vision for ATAI's mission and solution",
      "position": 1,
      "objective": "Present a compelling vision for ATAI's mission and solution",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}